Hence, since IFN-γ and IL-17 are probably not the critical determinants of whether an effector T cell is capable of trafficking to the CNS and inducing inflammatory demyelination, the focus of research on effector T cells in MS should be on upstream pathways driving Th1 and Th17 cells. The gene discussed is IL17A; the disease is myeloid sarcoma.